- Home
- WGSWW vs CCIA Comparison
WGSWW vs CCIA Comparison
Compare WGSWW & CCIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WGSWW
- CCIA
- Stock Information
- Founded
- WGSWW 2017
- CCIA N/A
- Country
- WGSWW United States
- CCIA
- Employees
- WGSWW N/A
- CCIA N/A
- Industry
- WGSWW Retail: Computer Software & Peripheral Equipment
- CCIA
- Sector
- WGSWW Technology
- CCIA
- Exchange
- WGSWW Nasdaq
- CCIA Nasdaq
- Market Cap
- WGSWW N/A
- CCIA N/A
- IPO Year
- WGSWW N/A
- CCIA 2023
- Fundamental
- Price
- WGSWW $0.21
- CCIA $25.76
- Analyst Decision
- WGSWW
- CCIA
- Analyst Count
- WGSWW 0
- CCIA 0
- Target Price
- WGSWW N/A
- CCIA N/A
- AVG Volume (30 Days)
- WGSWW 36.6K
- CCIA N/A
- Earning Date
- WGSWW 02-18-2025
- CCIA N/A
- Dividend Yield
- WGSWW N/A
- CCIA N/A
- EPS Growth
- WGSWW N/A
- CCIA N/A
- EPS
- WGSWW N/A
- CCIA N/A
- Revenue
- WGSWW $305,450,000.00
- CCIA N/A
- Revenue This Year
- WGSWW N/A
- CCIA N/A
- Revenue Next Year
- WGSWW N/A
- CCIA N/A
- P/E Ratio
- WGSWW N/A
- CCIA N/A
- Revenue Growth
- WGSWW 50.79
- CCIA N/A
- 52 Week Low
- WGSWW $0.17
- CCIA N/A
- 52 Week High
- WGSWW $0.21
- CCIA N/A
- Technical
- Relative Strength Index (RSI)
- WGSWW N/A
- CCIA 45.83
- Support Level
- WGSWW N/A
- CCIA $25.61
- Resistance Level
- WGSWW N/A
- CCIA $25.82
- Average True Range (ATR)
- WGSWW 0.00
- CCIA 0.10
- MACD
- WGSWW 0.00
- CCIA 0.00
- Stochastic Oscillator
- WGSWW 0.00
- CCIA 51.72
About WGSWW GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.